Do Statins Reduce Plaque Buildup in Arteries?

Statins can reduce plaque buildup in arteries, but the effect depends heavily on how aggressively they lower LDL cholesterol and how you define “reduce.” Clinical trials using imaging probes threaded into coronary arteries have shown that intensive statin therapy shrinks plaque volume in a majority of patients, particularly when LDL cholesterol drops below about 70 mg/dL. Just as interesting, though, is what statins do to the character of plaque that remains: they tend to make it more stable and less likely to rupture, even when total plaque size barely changes.

Shrinkage Versus Stabilization

When researchers talk about statins and plaque, they are really describing two related but distinct phenomena. The first is quantitative regression, meaning plaque physically gets smaller. The second is qualitative stabilization, meaning the plaque’s internal makeup shifts in ways that make a heart attack less likely. These do not always happen together, and the distinction matters.

Plaque regression has traditionally been defined as either an increase in the artery’s inner diameter or a measurable reduction in plaque volume on imaging. More recently, researchers have argued that favorable changes in plaque composition, such as less lipid content or a thicker protective cap, should also count as regression, though there is no consensus on whether increased stability alone qualifies.¹ In practice, some patients on statins see their plaques shrink while others see the plaques hold steady in size but become structurally safer. Both outcomes are clinically meaningful.

What Imaging Studies Reveal About Plaque Volume

The strongest evidence for statins actually shrinking plaque comes from studies using intravascular ultrasound, a technique where a tiny probe is fed into a coronary artery during a catheterization procedure to measure plaque dimensions directly. Over the past two decades, these trials have repeatedly shown that lowering LDL cholesterol to very low levels with intensive statin therapy reduces overall plaque burden.²

In one study that followed patients for eight months on statin therapy, roughly 57% showed measurable plaque regression while about 43% had continued progression. The response was not uniform: patients who started with moderate or high cholesterol saw the most shrinkage, while those with already-low baseline cholesterol sometimes saw plaque continue to grow despite treatment.³ Another serial ultrasound study of patients after an acute coronary event found that about two-thirds showed plaque regression, with the average change in percent atheroma volume around −1.5%.⁴

Those percentage changes sound tiny, and they are. Plaque regression with statins is measured in fractions of a percent per year, not dramatic before-and-after transformations. But even small shifts in plaque volume correspond to real reductions in heart attacks and strokes, as we will see later.

How Statins Reshape What Is Inside the Plaque

The plaques most likely to cause a heart attack are not necessarily the biggest ones. They are the ones with a large pool of lipid underneath a thin, fragile fibrous cap. When that cap tears, a blood clot forms on the exposed material and can block the artery entirely. Statins appear to remodel these dangerous plaques from the inside out, making the cap thicker and the lipid core smaller.

Studies using optical coherence tomography, a light-based imaging technique that can measure the fibrous cap with high resolution, have documented this effect directly. In one trial, patients on statin therapy saw their fibrous cap thickness nearly double over the follow-up period, going from about 151 micrometers to 280 micrometers. A control group saw a much smaller increase.⁵ Patients with the thinnest caps at the start benefited the most, which is reassuring since those are the people at highest risk of plaque rupture.

A separate trial compared a higher dose of atorvastatin (20 mg) with a lower dose (5 mg) and found the higher dose produced a 69% increase in cap thickness versus 17% with the lower dose. The higher dose also shrank the lipid arc, a measure of how much fatty material sits inside the plaque, by about 27% compared with 8%.⁶ This stabilization effect may be just as protective as shrinking the plaque itself, possibly more so.

The LDL Threshold That Predicts Regression

Not everyone who takes a statin sees their plaque shrink. One of the strongest predictors of whether regression happens is how low LDL cholesterol actually falls during treatment. Research has converged on a threshold of roughly 70 mg/dL as the tipping point where plaque tends to stop growing and begins to recede.

A systematic review and meta-analysis of lipid-lowering trials found that patients whose LDL dropped below 70 mg/dL showed significant plaque regression in terms of both total plaque volume and percent atheroma volume. Those in the 70 to 80 mg/dL range also showed regression, though the effect was smaller. Above 100 mg/dL, the evidence for regression largely disappeared.⁷ An earlier long-term ultrasound study of the left main coronary artery pinpointed 75 mg/dL as the LDL level below which plaque stopped expanding on average.⁸ That 70 mg/dL target, which recurs across Japanese, European, and American treatment guidelines, sits right around this inversion point.⁹

This has practical implications. A person on a moderate-intensity statin who gets their LDL down to 95 mg/dL is likely slowing plaque growth and gaining cardiovascular protection, but they may not be reversing existing plaque. Pushing LDL lower, either by increasing the statin dose or adding a second drug, appears to be what tips the balance toward regression.

Higher Doses and Combination Therapies

Because the LDL level itself drives regression more than the specific drug used, the question of dose intensity and combination therapy matters. A randomized trial comparing low-dose and high-dose rosuvastatin in patients with stable angina found that both doses improved plaque stability, but the high dose was more effective at reducing plaque volume.¹⁰ An MRI-based study of aortic plaques told a similar story: patients on high-dose statins showed greater vessel wall shrinkage and lumen widening than those on low-dose therapy.¹¹

For patients who cannot reach target LDL levels on statins alone, adding ezetimibe can push plaque regression further. In the PRECISE-IVUS trial, 78% of patients on atorvastatin plus ezetimibe showed coronary plaque regression, compared with 58% on atorvastatin alone.¹² A meta-analysis confirmed that the combination significantly reduced total plaque volume compared with statin monotherapy.¹³

PCSK9 inhibitors, a newer class of injectable drugs, lower LDL even more aggressively and have shown incremental effects on plaque regression beyond what statins alone achieve.² These drugs are generally reserved for people at very high cardiovascular risk or those who cannot tolerate adequate statin doses, but they reinforce the broader principle: the lower you push LDL, the more plaque regresses.

How Long Does Regression Take

Plaque does not melt away in weeks. A systematic review examining the time course across carotid, coronary, and aortic plaques found that regression occurred after an average of roughly 20 months of treatment.¹⁴ Some studies have detected measurable changes sooner. One MRI-based study of carotid plaques found about a 6% reduction in plaque volume after just six months in patients whose statin therapy was increased. Patients who stayed on the same statin dose, however, showed no significant change over the same period.¹⁵

Longer follow-up tends to reveal larger effects. A two-year study using MRI to track aortic and carotid plaques under simvastatin therapy found 10 to 11% reductions in plaque wall thickness and area at 12 months, with further decreases of 12 to 20% at 18 and 24 months. A slight but significant widening of the artery’s internal opening appeared at those later time points.¹⁶ The takeaway: plaque regression is a slow, cumulative process. Expecting visible results after a few months of treatment is unrealistic for most people, and stopping a statin because an early scan looks unchanged would be a mistake.

The Calcification Paradox

If you have been on a statin for years and get a coronary calcium scan, you might be startled to see a high score. This is one of the most confusing aspects of statin therapy and a frequent source of alarm for patients.

Long-term statin use is associated with higher coronary artery calcium scores. One large study found the association was dose-dependent in terms of duration: compared with non-users, those on statins for five to ten years had roughly three times the odds of being in a higher calcium category, and those on statins for more than ten years had about four and a half times the odds, even after adjusting for baseline cardiovascular risk.¹⁷

This sounds alarming, but the calcification that statins promote is thought to be a different kind than the scattered, spotty calcium deposits found in unstable plaques. Statins appear to shift plaque composition from soft, lipid-rich, rupture-prone material toward dense, calcified tissue that forms a kind of protective shell. Research on carotid plaques has found that active high-dose statin use is associated with a shift from vulnerable lipid-core plaque toward more stable calcified plaque.¹⁸ In this framing, the rising calcium score is not a sign of worsening disease but a marker that dangerous plaque is being converted into a more harmless form. This is why cardiologists generally advise against using calcium scores to monitor statin effectiveness. The score can go up while cardiovascular risk goes down.

Effects Beyond Cholesterol Lowering

Statins reduce coronary events by about 30% relative to placebo in clinical trials, and not all of that benefit can be explained by LDL lowering alone.¹⁹ Researchers have identified several additional mechanisms, often called pleiotropic effects, that likely contribute to plaque stabilization independent of cholesterol.

One is anti-inflammatory activity. Atherosclerosis is fundamentally an inflammatory disease, and statins reduce circulating markers of inflammation. The reduction in C-reactive protein, a key inflammation marker, does not simply track with how much LDL falls; it appears to be a separate pharmacological effect.²⁰ Not all statins produce the same anti-inflammatory effect, which may partly explain why individual patients respond differently to different drugs in the class.²¹

Another mechanism involves the lining of blood vessels. Statins boost the production of nitric oxide in endothelial cells, the cells that form the inner surface of arteries.²² Nitric oxide relaxes blood vessels, discourages clot formation, and suppresses the inflammatory signals that drive plaque growth. These endothelial effects kick in through both cholesterol-dependent and cholesterol-independent pathways.²³ The practical implication is that even a patient whose LDL does not drop as much as hoped may still get meaningful vascular protection from a statin, though the plaque-shrinkage benefit specifically does seem to track closely with LDL reduction.

Does Plaque Regression Actually Prevent Heart Attacks

Plaque regression on imaging is only useful if it translates into fewer clinical events. The evidence suggests it does, though the connection is not perfectly linear. A meta-regression analysis found that for every 1% decrease in percent atheroma volume, the odds of major adverse cardiovascular events dropped by roughly 14 to 19% after adjustment.²⁴ In a separate study of patients with coronary artery disease, those whose fatty plaque progressed had a cardiac event rate of about 22%, compared with 5% among those whose plaque regressed.²⁵

These numbers reinforce that plaque regression is not just an interesting imaging finding. It corresponds to real-world protection. That said, researchers are careful to note that even with maximal LDL lowering, considerable residual cardiovascular risk persists in some patients.² Plaque biology involves more than just cholesterol: inflammation, clotting tendency, blood pressure, and metabolic health all play roles. Statins move the needle on several of these simultaneously, which is part of why they remain the backbone of treatment, but they do not erase all risk.

Sex Differences in Plaque Response

One finding that has emerged consistently from imaging trials is that women tend to show greater plaque regression than men on the same intensive statin therapy. An analysis of data from the SATURN trial, which compared high-intensity rosuvastatin with atorvastatin, found that women demonstrated significantly more regression in percent atheroma volume than men, despite starting with less plaque overall.²⁶ Female sex was independently associated with plaque regression even after accounting for other variables.

A pooled analysis of multiple intravascular ultrasound trials confirmed the pattern: women systematically demonstrated greater coronary plaque regression, especially when their LDL cholesterol reached very low levels.²⁷ There also appear to be sex-related differences in how individual statins perform, with some evidence of an interaction between sex and statin type.²⁸ The biological reasons are not fully understood, but hormonal differences, variations in plaque composition, and differences in vascular remodeling may all contribute. For clinical practice, the finding reinforces that intensive lipid lowering is worthwhile in both sexes, and that the benefits may be even more pronounced for women than outcome trials historically suggested.

Plaque Regression Outside the Coronary Arteries

Most plaque-regression research focuses on the coronary arteries because that is where blockages cause heart attacks. But atherosclerosis is a systemic disease, and statins affect plaques throughout the vascular tree. MRI studies of aortic and carotid plaques have shown parallel regression patterns: simvastatin reduced vessel wall thickness in both locations by 10 to 11% at one year and 12 to 20% by two years, with a modest widening of the artery lumen at later time points.¹⁶

This matters because carotid plaque is a major contributor to stroke risk, and peripheral artery disease in the legs, aorta, and elsewhere carries its own set of complications. The fact that statins affect plaque composition in the carotid bed the same way they do in the coronary arteries, pushing it from soft and vulnerable toward dense and calcified, suggests the stabilization mechanism is not artery-specific.¹⁸ It also means the benefits of statin therapy extend beyond heart attack prevention to stroke and potentially other vascular events, even when the primary conversation between a doctor and patient focuses on coronary risk.